GITR: A Promising Target in Tumor Immunotherapy – Empowered by ANT BIO PTE. LTD.

1. Concept

Glucocorticoid-Induced TNFR-Related Gene (GITR), also known as TNFRSF18, CD357, or AITR, is a pivotal type I transmembrane receptor belonging to the Tumor Necrosis Factor Receptor Superfamily (TNFRSF), which encompasses key immune modulators such as OX40, CD27, CD40, and 4-1BB. Its core biological function lies in regulating immune responses by activating effector T cells and attenuating the immunosuppressive effects of regulatory T cells (Tregs), thereby emerging as a crucial node in anti-tumor immunomodulation. GITR exerts its effects through interactions with specific ligands, triggering downstream signaling pathways that orchestrate T cell survival, proliferation, and functional activation—making it a highly promising target for advancing tumor immunotherapy.

2. Research Frontiers

In the past decade, immunotherapy has transformed cancer treatment, with monoclonal antibodies (mAbs) targeting immune checkpoints like PD-1, PD-L1, and CTLA-4 leading the way. However, the clinical challenge of non-response or acquired resistance in some patients, coupled with the limited efficacy of these therapies in "cold tumors" (characterized by low immune cell infiltration), has spurred the search for novel immunotherapeutic strategies. Beyond inhibiting co-inhibitory pathways, activating co-stimulatory signaling cascades has emerged as a compelling approach, and GITR agonist antibodies have garnered substantial attention in this field.

Recent research advancements have deepened our understanding of GITR biology:

• Identification of SECTM1A as a new endogenous ligand for GITR, expanding the complexity of GITR-mediated signaling networks (though its exact physiological role remains to be fully elucidated).
• Preclinical studies demonstrating that GITR agonist mAbs (e.g., DTA-1) exhibit robust anti-tumor activity in multiple syngeneic mouse models, including melanoma and cervical cancer, by enhancing effector T cell function and depleting tumor-infiltrating Tregs.
• Exploration of combination therapies involving GITR agonists with PD-1/PD-L1 inhibitors, CTLA-4 blockers, chemotherapy, radiotherapy, or vaccines, which have shown synergistic anti-tumor effects and improved treatment outcomes in preclinical models.
• Clinical evidence suggesting that tumors with high CD8+ and CD4+ T cell infiltration (e.g., lung cancer, renal cancer, melanoma) are more responsive to GITR-targeted therapy, and intratumoral administration of GITR mAbs may elicit stronger systemic anti-tumor immunity compared to intravenous delivery.

3. Research Significance

GITR-targeted research holds profound implications for addressing unmet clinical needs in oncology. By focusing on activating co-stimulatory pathways, it offers a complementary strategy to existing immune checkpoint inhibitors, potentially overcoming resistance and expanding the spectrum of treatable cancers. For "cold tumors," GITR activation could help convert them into "hot tumors" by enhancing immune cell infiltration and activation, thereby improving the responsiveness to immunotherapy.

Furthermore, understanding GITR’s dual role in regulating effector T cells and Tregs provides critical insights into immune homeostasis, which is not only relevant to cancer but also to autoimmune diseases and inflammatory disorders. From a translational perspective, GITR agonist mAbs and related combination therapies are advancing through clinical trials, with the potential to revolutionize treatment paradigms for various malignancies. For the scientific community, GITR serves as a model for exploring co-stimulatory receptor biology, driving innovations in immunotherapeutic target discovery and drug development.

4. Related Mechanisms, Research Methods, and Product Applications

Core Mechanisms

• Ligand-Receptor Interactions: GITR binds to its primary ligand GITRL (AITRL), a type II transmembrane protein that forms trimers (and can also exist as monomers or other multimers), as well as the newly identified ligand SECTM1A. GITRL is predominantly expressed by activated antigen-presenting cells (APCs) such as macrophages, B cells, and dendritic cells, with expression further induced on endothelial cells by type I interferons (IFNs).
• Signaling Pathways: Upon ligand binding, GITR recruits TNF receptor-associated factors (TRAFs), activating the nuclear factor-κB (NF-κB) pathway. This upregulates pro-survival molecules like Bcl-xL, inhibits T cell apoptosis, and promotes T cell survival. Additionally, GITR co-stimulation induces the expression of cytokines such as IL-2 and IFN-γ, upregulates CD25, and enhances T cell proliferation and cytotoxicity.
• Immune Modulation: GITR activation enhances the function of CD8+ and CD4+ effector T cells, including their cytotoxic activity and memory cell formation. Conversely, it suppresses Treg function—either by rendering effector T cells resistant to Treg-mediated suppression or directly inhibiting Tregs (possibly via transient loss of FoxP3 expression) through antibody-dependent cellular cytotoxicity (ADCC). Notably, short-term GITR/GITRL axis activation suppresses Tregs, while long-term overstimulation may promote Treg expansion, reflecting the complexity of its regulatory role.

Research Methods

• Expression Analysis: Techniques such as flow cytometry, immunohistochemistry (IHC), and quantitative PCR (qPCR) are used to detect GITR and GITRL expression on various immune cells (Tregs, effector T cells, NK cells) and tissue types.
• Functional Assays: In vitro experiments (e.g., T cell proliferation assays, cytokine secretion ELISAs, cytotoxicity assays) and in vivo syngeneic tumor models are employed to evaluate the effects of GITR activation on immune cell function and anti-tumor activity.
• Signaling Pathway Studies: Western blotting, immunoprecipitation, and reporter gene assays are utilized to dissect the NF-κB-dependent and other downstream signaling pathways mediated by GITR.
• Therapeutic Efficacy Evaluation: Preclinical studies assess the anti-tumor potential of GITR agonist mAbs as monotherapy or in combination with other treatments, measuring tumor growth inhibition, survival rates, and immune cell infiltration in tumor tissues.

Product Applications by ANT BIO PTE. LTD.

ANT BIO PTE. LTD., through its specialized sub-brands, provides high-quality research tools tailored to GITR-focused studies:

• STARTER Brand (Antibodies): Offers GITR-specific agonist monoclonal antibodies, anti-GITR/ GITRL detection antibodies, and Treg/effector T cell marker antibodies (e.g., anti-FoxP3, anti-CD8, anti-CD4), enabling precise detection of GITR expression and functional evaluation of GITR-mediated immune modulation.
• UA Brand (Recombinant Proteins): Supplies recombinant GITRL (AITRL) proteins (human and mouse variants) that facilitate in vitro GITR activation assays and ligand-receptor interaction studies. Key products include UA040088 (Mouse AITRL Protein, E.coli-expressed, unconjugated) and UA040214 (Human AITRL Protein, E.coli-expressed, unconjugated), which are critical for validating GITR signaling pathways and screening GITR-targeted molecules.
• Absin Brand (Kits & General Reagents): Provides ELISA kits for quantifying cytokines (IL-2, IFN-γ, IL-10) involved in GITR signaling, as well as general reagents for cell culture, flow cytometry staining, and protein extraction—supporting seamless experimental workflows from in vitro assays to in vivo sample analysis.

5. Brand Mission

At ANT BIO PTE. LTD., our mission is to empower global life science researchers and translational scientists by delivering high-quality, reliable reagents and tools that accelerate breakthroughs in immunology and oncology. We are committed to supporting the exploration of cutting-edge targets like GITR through our specialized sub-brands: STARTER (antibodies), UA (recombinant proteins), and Absin (kits & general reagents). Leveraging advanced development platforms (including recombinant monoclonal antibody technology, multi-system protein expression platforms, and One-Step ELISA platforms) and rigorous quality control systems (compliant with EU 98/79/EC, ISO9001, and ISO13485 certifications), we strive to provide tailored solutions that meet the unique needs of GITR research—from basic biological mechanism studies to preclinical therapeutic development. Our dedication to innovation, quality, and customer-centricity drives us to contribute to the advancement of tumor immunotherapy and improve global health outcomes.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.